Drug intelligence / Profile preview

cisplatin + fluorouracil + leucovorin

Development stage: Unknown
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Intravenous

Overview

This combination is used in chemotherapy for treating various cancers, including head and neck squamous cell carcinoma and recurrent head and neck cancer. Cisplatin is a platinum-based antineoplastic drug, fluorouracil (5-FU) is a pyrimidine analog, and leucovorin is a folinic acid derivative that enhances the efficacy of 5-FU by stabilizing its active metabolite. The combination works by inducing DNA damage and inhibiting DNA synthesis.

Other names: PFL

Targets

TS (Thymidylate synthase)DNA

Beyond the preview

Go deeper on cisplatin + fluorouracil + leucovorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + fluorouracil + leucovorin.

Explore the full profile